The Competition Commission of India (CCI) approves the acquisition of less than 5% shareholding in Intas Pharmaceuticals Limited by Canary Investments Limited and Link Investment Trust II, under Section 31(1) of the Competition Act, 2002.

The Proposed Combination relates to acquisition of less than 5% shareholding ofIntas Pharmaceuticals Limited (Intas) by Canary Investments Limited (Canary) and Link Investment Trust II (Link II).

Canary is an investment company registered in Mauritius. Link II is a private trust created and registered under the laws of India.Intas is a public limited company incorporated and registered under the laws of India. Intas is said to be a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company.

The Commission approved the Proposed Combination subject to the carrying out of modifications proposed by Canary and Link II.

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world.

Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

All products are manufactured in facilities that are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more. Today, a segment-leading pipeline and strong in-house development capabilities allow Intas to compete with some of the biggest portfolios in the industry. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to continue raising the bar of healthcare excellence, globally in the near future.